Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 6:03 AM EDT-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million
-81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse
-Company to Host Quarterly Conference Call at 8:30 am ET Today
CORAL GABLES, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results... More
